NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Citizen Science x Phenomenology
Journaling, editing, reflecting, integrating – all remain valid when formalising your anecdotal report, to make sense of everything you experienced during your protocol. But, what if the quality of your microdosing e...
The Psychedelic Future We Were Promised
This Week's Sunday Insider: Why the Psychedelic Future Never Arrived.
Let them eat Bufo
What happens when a powerful drug used by privileged bohemians becomes a medical treatment for the masses? Let's find out!
Weekly Psychedelic Policy Briefing – August 14, 2026
The FDA has finalized guidance on clinical investigations into psychedelic-assisted therapies and contract research organization ICON will bring Anthropic's Claude AI tool into clinical trials involving drug developme...
Report highlights substance use in young adults in US in 2025
Cannabis use remains high among young adults in the United States, according to a report issued by the University of Michigan.
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
CAMBRIDGE, Mass., August 14, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address…
Veterans Affairs continues to drive federal psychedelics push; New FDA guidance; and Resilient Pharmaceuticals tries again for MDMA approval
Plus: Pharmaceutical giant Eli Lilly makes a psychedelics acquisition; Cardiovascular safety is top of mind for psychedelics researchers
9 Questions I'm Obsessed With About Psychedelics Right Now
Welcome to The Psychedelic Blog. Bestselling essayist & Psychedelic cultural analyst examining how altered states shape relationships, grief, death & meaning.
Puerto Rico Makes Moves on Ibogaine, MDMA, and Psilocybin
The island's governor just signed an executive order effectively launching a pilot program to research psychedelic therapy. [...] Read More... The post Puerto Rico Makes Moves on Ibogaine, MDMA, and Psilocybin appeare...
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum" or the "Company"), has reported its financial and operational results for the…
Why Perimenopause Belongs in Psychedelic Research
Perimenopause is one of the least-researched transitions in women's health. Some women are already microdosing San Pedro to get through it. Deva Collective's founder on why that experience deserves to be studied, not ...
Blood biomarker changes in response to low-dose oral ketamine treatment in adults with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD)
This secondary analysis across two trials (n=35) examined blood biomarkers and psychological changes in adults with major depressive disorder, with or without post-traumatic stress disorder, after low-dose oral ketami...
Microdosing for Anxiety: What the Evidence Shows, and Where It Doesn’t
Microdosing for anxiety looks encouraging in open-label surveys and far less convincing under placebo control. What facilitators need to know about the evidence, the protocols, the contraindications, and the backfire ...
Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study
What happens when a psychedelic experience continues causing problems long after the trip ends? Emory researchers Josh Lipson and Roman Palitsky discuss psychedelic harms, HPPD, spiritual crisis, adverse events, and t...
Newly engineered psychedelic shows therapeutic promise without gastrointestinal distress
A recently developed psychedelic compound promotes brain plasticity and reduces anxiety in mice without triggering gastrointestinal distress. The findings provide a chemical blueprint for designing safer, more tolerab...